• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

    2/12/25 4:35:31 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Twist Bioscience Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    90184D100

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    90184D100


    1Names of Reporting Persons

    WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,632,652.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,949,723.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,949,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Twist Bioscience Corp
    (b)Address of issuer's principal executive offices:

    681 GATEWAY BLVD., 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CALIFORNIA, 94080.
    Item 2. 
    (a)Name of person filing:

    William Blair Investment Management, LLC
    (b)Address or principal business office or, if none, residence:

    150 North Riverside Plaza, Chicago, IL 60606
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    90184D100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,949,723
    (b)Percent of class:

    5.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,632,652

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2,949,723

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
     
    Signature:Stephanie Braming
    Name/Title:Partner, Global Head of Investment Management
    Date:02/12/2025
    Get the next $TWST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    2/7/2022$130.00 → $75.00Overweight
    Barclays
    More analyst ratings

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Twist Bioscience with a new price target

      Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

      12/13/24 8:32:53 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Twist Bioscience with a new price target

      Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

      6/4/24 7:44:10 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience upgraded by Goldman with a new price target

      Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously

      1/17/24 7:47:50 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions

      Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. This press release features multi

      5/22/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference

      Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bios

      5/15/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units ("RSUs") and up to 19,379 performance stock units ("PSUs"), to 36 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accor

      5/13/25 8:00:00 AM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

      For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

      3/26/21 3:51:09 PM ET
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care